PDCD1 and neoplasm: The results from a first-in-human clinical trial (NCT02828098) combining B0-112 with anti-PD-1 therapy demonstrated tumour cell necrosis, apoptosis, and immune re-activity, suggesting this therapy could be used to overcome immune-checkpoint inhibitor-resistant tumours [134].